Cited by 33T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Learning from the nexus of autoimmunity and cancer

Open access
Mangani, Davide, Yang, Dandan, Anderson, Ana C.·2023·Immunity

Abstract

The immune system plays critical roles in both autoimmunity and cancer, diseases at opposite ends of the immune spectrum. Autoimmunity arises from loss of T cell tolerance against self, while in cancer, poor immunity against transformed self fails to control tumor growth. Blockade of pathways that preserve self-tolerance is being leveraged to unleash immunity against many tumors; however, widespread success is hindered by the autoimmune-like toxicities that arise in treated patients. Knowledge gained from the treatment of autoimmunity can be leveraged to treat these toxicities in patients. Further, the understanding of how T cell dysfunction arises in cancer can be leveraged to induce a similar state in autoreactive T cells. Here, we review what is known about the T cell response in autoimmunity and cancer and highlight ways in which we can learn from the nexus of these two diseases to improve the application, efficacy, and management of immunotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2023.01.022

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibitory receptor deficiencies or checkpoint therapies can cause or exacerbate AIDs.

    “Inhibitory receptor deficiencies or checkpoint therapies can cause or exacerbate AIDs, 37,61”

    From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [37]

    The section 'Regulation of T cell responses by immune checkpoint receptors' (page unavailable) reports that CTLA-4 or PD-1 deficiency can lead to autoimmunity. The Introduction and 'Leveraging biomarkers, pharmacogenomics, and GWAS to predict therapy response and irAEs' (pages unavailable) say checkpoint blockade can cause immune-related adverse events through disrupted tolerance, but do not establish that it exacerbates pre-existing autoimmune diseases. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • A dominant role for exhausted autoantigen-specific T cells in AID patients is at odds with the current view of pro-inflammatory activated T cells driving chronic autoimmunity.

    “A dominant role for exhausted autoantigen-specific T cells in AID patients is at odds with the current view of pro-inflammatory activated T cells driving chronic autoimmunity. 37”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [44]Borghans JAM, Keşmir C, De Boer RJ. MHC diversity in Individuals and Populations. In: Flower D, Timmis J, editors. In Silico Immunology. Boston, MA: Springer US; 2007. p. 177– 95.

Cited by

Sorted by citations

Authors
Mangani, D., Yang, D., & Anderson, A. C.
Affiliations
Harvard University (US)
Corresponding author
  • Mangani, Davide
  • Anderson, Ana C.
Venue
Immunity
Publisher
Elsevier BV
Published
2023-02
Volume
56
Issue
2
Pages
256-271
ISSN
1074-7613 (ISSN-L)
OpenAlex
W4320730787
Cited by
33
References
210
Citations by year
2026: 6 · 2025: 11 · 2024: 12 · 2023: 4
FWCI
0.92
Type
journal article
Language
en
Open access
Locations
  • Immunity (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Melanoma Research Alliance (824733)
  • Brigham and Women's Hospital
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (183910)
  • National Institutes of Health
  • National Cancer Institute (P01CA236749, R01CA229400, R01CA187975, R01CA246653)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
autoimmunity, cancer immunotherapy, T cell tolerance, immune checkpoint blockade, T cell dysfunction, autoreactive T cells, antitumor immunity, immunotherapy toxicity management
MeSH terms
Autoimmune Diseases, Humans, Immune Tolerance, Neoplasms, T-Lymphocytes, Autoimmunity, Self Tolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review